NAD+ Augmentation: Nicotinamide Mononucleotide (NMN) vs. Nicotinamide Riboside (NR)
Both NMN and NR effectively raise circulating and tissue NAD+ levels, but intense debate surrounds whether NMN is directly imported via the Slc12a8 transporter or dephosphorylated extracellularly into NR prior to cell entry.
Position A: Pro-NMN (Direct Transporter & Tissue Bioavailability)
Camp ADr. David Sinclair
Harvard Medical School
NMN utilizes the dedicated Slc12a8 transporter discovered in small intestine and brain tissue, enabling direct, rapid uptake without prerequisite enzymatic cleavage into NR. Human clinical trials (e.g. Yi et al., 2023) show robust 2-fold increases in blood NAD+ and significant improvements in 6-minute walking distances and biological age metrics.
Position B: Pro-NR (Proven Nucleoside Uptake Pathway)
Camp BDr. Charles Brenner
City of Hope National Medical Center
NMN is a polar mononucleotide with a charged phosphate group that cannot freely cross lipid bilayers; CD73 ecto-5-nucleotidase must dephosphorylate NMN into NR extracellularly before equilibrative nucleoside transporters (ENTs) can import it. NR enters cells directly via ubiquitous ENTs and is phosphorylated by NRK1/2, making NR the biochemically efficient, universally utilized NAD+ precursor.